Diagnostics company Guardant Health (NASDAQ:GH) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 44.3% year on year to $335 million. The company’s full-year revenue guidance of $1.35 billion at the midpoint came in 2.7% above analysts’ estimates. Its non-GAAP loss of $0.42 per share was 7.8% below analysts’ consensus estimates.
Is now the time to buy GH? Find out in our full research report (it’s free for active Edge members).
Guardant Health (GH) Q2 CY2026 Highlights:
- Revenue: $335 million vs analyst estimates of $314.7 million (44.3% year-on-year growth, 6.4% beat)
- Adjusted EPS: -$0.42 vs analyst expectations of -$0.39 (7.8% miss)
- Adjusted EBITDA: -$55.9 million (-16.7% margin, 7.7% year-on-year decline)
- The company lifted its revenue guidance for the full year to $1.35 billion at the midpoint from $1.31 billion, a 3.1% increase
- Operating Margin: -38.5%, up from -45.9% in the same quarter last year
- Market Capitalization: $21.74 billion
StockStory’s Take
Guardant Health’s second quarter results were marked by significant revenue growth, exceeding Wall Street’s expectations and generating a positive reaction from investors. Management attributed this performance to robust volume acceleration in its Oncology business, particularly through the adoption of Guardant360 Liquid and Reveal products, as well as rapid expansion in its Screening segment. Co-CEO Helmy Eltoukhy highlighted, “The tremendous 63% growth in Oncology volume represented another quarter of acceleration, reflecting the increasing strength of our portfolio across both therapy selection and MRD.”
Looking ahead, Guardant Health’s outlook is shaped by newly expanded coverage for its Shield blood test, the phased rollout of FDA-approved Guardant360 Liquid CDx, and ongoing investments in laboratory capacity. Management emphasized that broader commercial insurance coverage and guideline inclusions are expected to increase test volumes, while cost-per-test reductions should support margin improvement. CFO Michael Bell stated, “Combined with additional efficiencies from increasing scale, we expect that by the end of 2026, Shield cost per test will reduce by roughly 15% from the current level of approximately $410.”
Key Insights from Management’s Remarks
Management credited volume gains in Oncology and Screening, improved lab efficiency, and recent regulatory milestones as central to Q2 performance, while noting that higher operating expenses reflected continued commercial investment.
-
Oncology volume acceleration: Guardant Health saw 63% year-over-year growth in Oncology test volumes, with strong adoption across Guardant360 Liquid, Guardant360 Tissue, and Reveal. Management highlighted that Reveal, its minimal residual disease (MRD) test, experienced volume growth of over 100% as therapy monitoring gained traction among oncologists.
-
FDA approvals drive adoption: The company received FDA approval for Guardant360 Liquid CDx, the only FDA-approved liquid biopsy test integrating genomic and epigenomic content, and for a higher-throughput, lower-cost Shield workflow. These regulatory milestones are expected to simplify the therapy selection portfolio and increase Shield’s lab efficiency.
-
Shield screening momentum: Shield, Guardant’s blood-based colorectal cancer screening test, posted revenue growth driven by commercial, direct-to-consumer, and Quest Diagnostics collaboration channels. Inclusion in major screening guidelines and UnitedHealth Group’s coverage decision expanded Shield’s covered population to roughly 70 million lives, or about 60% of the market.
-
Strategic data asset expansion: Management emphasized the compounding value of its proprietary data repository, now spanning over 1.3 million patient tests and more than 700,000 epigenetic profiles. This data underpins the InfinityAI platform, supporting both clinical applications and biopharma partnerships.
-
Operating margin improvement: While adjusted EBITDA loss widened year-over-year, operating margin improved from -45.9% to -38.5%, supported by cost reductions from lab automation, particularly the transition to NovaSeq X and the new Shield workflow. Cost control was offset by higher sales and marketing investments to support commercial expansion.
Drivers of Future Performance
Management expects future growth to be propelled by expanded insurance coverage, commercial execution in Shield, and continuous product innovation, with investments in lab automation and efficiency supporting profitability targets.
-
Broader Shield access boosts volumes: The addition of UnitedHealth Group coverage and inclusion in American Cancer Society guidelines significantly increases Shield’s addressable market. Management anticipates that these developments, along with ongoing commercial partnerships, will drive sequential volume growth and broaden patient access, though average selling price (ASP) improvements will take longer as payer negotiations continue.
-
Margin tailwinds from automation: Implementation of a higher-throughput, lower-cost Shield workflow and full transition of Guardant360 Liquid to NovaSeq X are expected to reduce cost per test and bolster gross margins. Management aims for a further 15% reduction in Shield’s cost per test by the end of 2026, with additional scale and automation initiatives planned for 2028.
-
Product pipeline and reimbursement wins: The launch of Reveal Ultra, further reimbursement submissions for Reveal in breast cancer and therapy monitoring, and anticipated ADLT (Advanced Diagnostic Laboratory Test) designation for Guardant360 Liquid CDx are identified as key milestones. Successful execution on these fronts could increase both volume and ASP, accelerating the company’s timeline to cash flow breakeven.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will closely watch (1) the pace of Shield volume growth following UnitedHealth Group coverage and ACS guideline inclusion, (2) progress in securing additional payer reimbursement and ADLT designation for Guardant360 Liquid CDx, and (3) the commercial launch and uptake of Reveal Ultra. Execution in lab automation, data-driven product enhancements, and successful payer negotiations will be critical signposts for Guardant Health’s long-term growth trajectory.
Guardant Health currently trades at $161.50, up from $152.35 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.